Last reviewed · How we verify
Oseltamivir 3 days
At a glance
| Generic name | Oseltamivir 3 days |
|---|---|
| Also known as | 3-days postexposure chemoprophylaxis with oseltamivir |
| Sponsor | Centre of Postgraduate Medical Education |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients (PHASE2)
- Severe Influenza Trial of ARbidol (PHASE3)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses (PHASE1)
- A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (PHASE1)
- A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A (PHASE3)
- Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oseltamivir 3 days CI brief — competitive landscape report
- Oseltamivir 3 days updates RSS · CI watch RSS
- Centre of Postgraduate Medical Education portfolio CI